Amanda Forys, MSPH: I know the oncology care model has been something that we’re testing out to see if more involved provider interaction and treating that patient in the Medicare world on an almost per-member, per-month basis where you’re giving that provider that payment to manage the patient.
Do you think payment systems like that—that do some type of encapsulated full service, or comprehensive service, more involved with Medicaid or more involved for the uninsured even just making sure that offices are doing that beyond Medicare—that that’s the kind of model that you’d like to see?
Christy M. Gamble, JD, DrPH, MPH: Yes, that’s a great model to follow. It really is. Like I said, there’s still those little holes and gaps where if you work with those specific population advocacy groups we can fill those, but really giving that specialized attention to the patient is what’s really needed.
Medicare is doing some things very well, and doing some things not so great. We’re all for innovation and trying out things to see where the gaps are. I would hate to say, “No it’s not working,” I would rather say that “It’s going along very well, but we still see some gaps that we would like to fill there.”
But coming up with ideas and being really innovative in reaching every patient population—we’re always giving a thumb up for that.
Amanda Forys, MSPH: Yes, coordinated care models, I know we’re always trying to figure out better ways to provide coordinated care, so I definitely think that since you mentioned the medical transport, getting people to where they need to be and thinking about that, it’s a broader spectrum of treating the patient, not just the disease that’s important.
Christy M. Gamble, JD, DrPH, MPH: Yes, absolutely.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Skyrizi Overtakes Humira: “Product Hopping” Leaves Biosimilar Market in Limbo
November 7th 2024For the first time, Skyrizi (risankizumab-rzaa) has replaced Humira (reference adalimumab) as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Eye on Pharma: Henlius, Organon Updates; Meitheal Portfolio Expansion; Celltrion Zymfentra Data
November 5th 2024Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous infliximab (Zymfentra) showed monotherapy could be as effective as combination therapy for inflammatory bowel disease.